Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

21 May 2009

Results of treatment of patients with acute liver failure (ALF) with use Prometheus® FPSA system

M Grodzicki, M Kotulski, D Leonowicz, K Zieniewicz, M Krawczyk

Ann Transplant 2009; 14(1): 28-28 :: ID: 880301

Abstract

Background: The authors present the results of treatment of patients with  acute liver failure with the use of Prometheus FPSA dialysis system.
Material/Methods: Until August 2008 there were performed 248 FPSA procedures in 104 patients. 44 patients were introduced to FPSA treatment due to acute liver failure. Group of patients who underwent FPSA procedure consisted of 27 women / 17 men, with mean age 31±12. Causes of acute liver failure were: Wilson's disease (14), unknown origin ALF (8), amanita phalloides intoxication (7), paracetamol intoxication (6), acute HBV/HCV infection (4), liver insufficiency after parenchymal resection (2), DRESS Syndrome (1), rhabdomyolysis (1), PNF after OLTx (1). All procedures were performed with Prometheus® 4008H Fresenius Medical Care liver support system. Average number of treatments for 1 patient was 2.38 and average time of FPSA treatment was 6.2 h. Average heparin dose used during procedure was 750 i.u/h.
Results: After whole treatment significant improvement of the biochemical
tests results was observed. Average concentration of serum ammonia (before
239.2 ug/dl, after 105.8 ug/dl); bilirubin (before 26.4 mg/dl, after 6.81 mg/dl). Average serum aminotransferase activity AST (before 2156.4 U/L, after 1094.8 U/L); ALT (before 2698.2 U/L, after 1434.8 U/l). Average concentration of serum urea (before 67.6 mg/dl, after 27.1 mg/dl); creatinine (before 2.6 mg/dl, after 1.3 mg/dl). Mean pH value (before 7.19, after 7.36). After Prometheus treatment liver transplantation was performed in 27 patients. 24 patients survived (54.5%); 19 patients FPSA+OLTx, 5 patients without OLTx. 20 patients died (45.4%); 12 before OLTx, and 8 after OLTx.
Conclusions: 1. Usage of FPSA system is a useful method of detoxication in a group of patients with acute liver failure (ALF). 2. Prometheus® 4008H  Fresenius Medical Care liver support system can be considered as an element of liver function support before transplantation.

Keywords: Liver Transplantation, clinical outcome

Add Comment 0 Comments

In Press

08 Mar 2024 : Original article  

Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...

Ann Transplant In Press; DOI: 10.12659/AOT.943532  

14 Mar 2024 : Original article  

Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort Study

Ann Transplant In Press; DOI: 10.12659/AOT.943652  

14 Mar 2024 : Case report  

Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...

Ann Transplant In Press; DOI: 10.12659/AOT.942358  

15 Mar 2024 : Review article  

Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighti...

Ann Transplant In Press; DOI: 10.12659/AOT.941185  

Most Viewed Current Articles

05 Apr 2022 : Original article  

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

12 Jan 2022 : Original article  

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

22 Nov 2022 : Original article  

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358